0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-147.52%PremiumJul 19, 2024Expiry Date2.98Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.70Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet